Illumina Completes $800M Notes Offering; Buys Back Shares | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Friday that it has closed its offering of $800 million principal amount of .25 percent convertible senior notes due 2016.

The San Diego-based firm announced the offering earlier in the week, and said that it also has granted initial purchasers a 30-day option to purchase up to $120 million of additional notes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.